Lexeo Therapeutics ' stock could nearly double as its gene therapies advance through its pipeline, according to JPMorgan. That implies a potential upside of nearly 82% from the stock's Monday closing price of $11. LXEO ALL mountain Lexeo Therapeutics all-time stock chart Analyst Tessa Romero cited Lexeo Therapeutics' lead cardiac therapy, LX2006, as a catalyst for the stock. The gene therapy is delivered to body tissues through an adeno-associated virus vector and it targets a rare genetic heart disorder called Friedreich's ataxia cardiomyopathy. The firm is also evaluating a similar type of gene therapy, LX2020, to treat cases of PKP2-ACM, another kind of inherited heart disease.

---

Persons: Tessa Romero, Lexeo, Romero, LX2020, LX1001, – LX2006, Michael Bloom Organizations: Therapeutics, JPMorgan, Lexeo Therapeutics, ACM, ~$ Locations: U.S